Angina News and Research

RSS

Angina is chest pain or discomfort that occurs when an area of your heart muscle doesn't get enough oxygen-rich blood. Angina may feel like pressure or squeezing in your chest. The pain also may occur in your shoulders, arms, neck, jaw, or back. It can feel like indigestion.

'Pacemaker' Hcn4 gene responsible for generation of repetitive activity in SAN tissue and heart rate regulation

The study of Dario DiFrancesco and his equipe identifies the "pacemaker" Hcn4 gene as the gene functionally responsible for the generation of repetitive activity in sinoatrial node tissue and for the regulation of heart rate. Hcn4 codes for HCN4 channels, the molecular components of "funny" ion channels of pacemaker cells of the sinoatrial node (SAN) tissue.

14 Jan 2011

Investigators find reduction in STEMI rates, but slight increase in NSTEMI incidence rates

Coronary syndromes vary in severity, ranging from unstable angina, non-ST segment elevation myocardial infarction, to ST-segment elevation myocardial infarction, the most severe diagnosis. Little data exist about changing trends in acute myocardial infarction and whether death rates are increasing or decreasing.

13 Jan 2011

NovaDel receives $500,000 milestone payment from Akrimax in connection with NitroMist agreement

NovaDel Pharma Inc. today announced that it has received a $500,000 milestone payment from Akrimax Pharmaceuticals. The milestone payment was received in connection with the license and distribution agreement, dated October 27, 2009, between NovaDel Pharma Inc. and Mist Acquisition, LLC, an affiliate of Akrimax Pharmaceuticals.

7 Jan 2011

FDA approves Novartis' Amturnide for treatment of high blood pressure

Today Novartis announced that the US Food and Drug Administration (FDA) approved Amturnide (aliskiren, amlodipine and hydrochlorothiazide) tablets for the treatment of high blood pressure. Amturnide combines the only approved direct renin inhibitor worldwide, Tekturna (aliskiren), with the widely used calcium channel blocker amlodipine and the diuretic hydrochlorothiazide (HCTZ).

23 Dec 2010

Aromatase inhibitors raise risk of cardiovascular disease in postmenopausal breast cancer patients

Postmenopausal women who take aromatase inhibitors as a treatment for breast cancer may be at an increased risk for developing cardiovascular disease, according to the results of a meta-analysis.

10 Dec 2010

Nottingham researchers develop new 'score' to detect heart disease in younger people

Experts at The University of Nottingham have developed a new 'score' to help GPs detect heart disease in younger people - before it damages their health.

9 Dec 2010

Sheathless transradial intervention highly successful in treating complex lesions

Cardiologists from the Mayo Clinic performed sheathless transradial percutaneous coronary intervention (PCI) to remedy complex lesions, achieving a 90% success rate with no radial complications. Standard guiding catheters were used during the procedure. Details of this novel approach—overcoming the last hurdle to greater adoption of transradial PCI in the U.S.—are published in the December issue of Catheterization and Cardiovascular Intervention, the official journal of The Society for Cardiovascular Angiography and Interventions.

7 Dec 2010

Cardiologists achieve 90% success rate in sheathless transradial PCI to remedy complex lesions

7 Dec 2010

Emergent declares one-time cash dividend and regular dividend

Emergent Group Inc., a leading provider of mobile medical lasers and surgical equipment, today announced that the Board of Directors has declared a special, one-time cash dividend of $0.50 per share on its common stock as well as a regular dividend of $0.40 per share, for a total of $0.90 payable December 27, 2010 to shareholders of record December 17, 2010.

7 Dec 2010

Studies shows that social stress accelerates atherosclerosis development

Studies on genetically engineered mice show that social stress activates the immune system and accelerates the development of atherosclerosis. Commonly used drugs to reduce blood pressure, however, may stop this process. This is the conclusion of a thesis presented at the University of Gothenburg, Sweden.

7 Dec 2010

Aspirin decreases plaque formations that cause heart attacks and strokes

Charles H. Hennekens, M.D., DrPH, the first Sir Richard Doll Research Professor in the Charles E. Schmidt College of Medicine at Florida Atlantic University, has published the results of A Randomized Trial of Aspirin at Clinically Relevant Doses and Nitric Oxide Formation in Humans in the current issue of the Journal of Cardiovascular Pharmacology and Therapeutics.

2 Dec 2010

Shire reports topline results from FAST-3 Firazyr Phase III trials for acute attacks of hereditary angioedema

Shire plc, the global specialty biopharmaceutical company, today announced topline results from FAST-3 (For Angioedema Subcutaneous Treatment), the largest of the Phase III trials studying the use of Firazyr (icatibant) for treatment of acute attacks of hereditary angioedema (HAE).

2 Dec 2010

Micell initiates enrollment in DESSOLVE I clinical trial of MiStent DES

Micell Technologies,™ Inc. today announced it has enrolled at Mercy Hospital in Auckland, New Zealand, the first patient in DESSOLVE I (DES with Sirolimus and a bioabsorbable pOLymer for the treatment of patients with de noVo lEsions in the native coronary arteries), a first-in-human clinical trial of the company's investigational MiStent™ Drug Eluting Coronary Stent System (MiStent DES).

29 Nov 2010

CIHI study finds impact of H1N1 pandemic on Canadian hospitals

While the H1N1 global pandemic may not have resulted in as many severe cases as originally predicted, a new study released today by the Canadian Institute for Health Information (CIHI) shows that more than 15,000 Canadians were admitted to hospital for H1N1 in Canada between April and December 2009.

24 Nov 2010

Sun Pharma receives FDA approval for generic Tiazac ANDA

Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of once-a-day Tiazac® extended release capsules.

18 Nov 2010

Researchers report results from Phase III DEFINE study for coronary heart disease

Researchers today presented results from the Phase III DEFINE (Determining the EFficacy and Tolerability of CETP INhibition with AnacEtrapib) study with Merck's investigational CETP inhibitor, anacetrapib. In the trial of 1,623 patients with coronary heart disease (CHD) or CHD risk equivalents, anacetrapib showed no significant differences from placebo in the primary safety measures studied.

18 Nov 2010

TRITON–TIMI 38 substudy shows prasugrel reduces overall mortality rate in ACS patients

New results from an observational substudy from TRITON–TIMI 38 presented today at the American Heart Association (AHA) Scientific Sessions annual meeting showed that patients treated with Efient/Effient (prasugrel) prior to coronary artery bypass graft surgery (CABG) had a reduced overall mortality rate compared to patients treated with Plavix (clopidogrel)

17 Nov 2010

PLC Systems third quarter net loss decrease to $5,000

PLC Systems Inc., a company focused on innovative cardiac and vascular medical device-based technologies, today reported financial results for the three- and nine-month periods ended September 30, 2010.

15 Nov 2010

Pharmaxis to present ARIDOL Bronchial Challenge Test Kit at 2010 ACAAI

Pharmaxis, a global specialty pharmaceutical company focused on therapeutic products for respiratory and immune disorders, will present ARIDOL™ (mannitol inhalation powder) Bronchial Challenge Test Kit, at the 2010 Annual Meeting of the American College of Allergy, Asthma and Immunology (ACAAI), November 11-16 in Phoenix, AZ.

11 Nov 2010

New Canadian Cardiovascular Society guidelines support clinicians in practicing evidence-based medicine

Summaries of a number of new Canadian Cardiovascular Society guidelines and position statements offering the most up to date information to support clinicians in practicing evidence-based medicine were released at the Canadian Cardiovascular Congress 2010 this week.

25 Oct 2010

Angina News and Research

Further Reading

'Pacemaker' Hcn4 gene responsible for generation of repetitive activity in SAN tissue and heart rate regulation

Investigators find reduction in STEMI rates, but slight increase in NSTEMI incidence rates

NovaDel receives $500,000 milestone payment from Akrimax in connection with NitroMist agreement

FDA approves Novartis' Amturnide for treatment of high blood pressure

Aromatase inhibitors raise risk of cardiovascular disease in postmenopausal breast cancer patients

Nottingham researchers develop new 'score' to detect heart disease in younger people

Sheathless transradial intervention highly successful in treating complex lesions

Cardiologists achieve 90% success rate in sheathless transradial PCI to remedy complex lesions

Emergent declares one-time cash dividend and regular dividend

Studies shows that social stress accelerates atherosclerosis development

Aspirin decreases plaque formations that cause heart attacks and strokes

Shire reports topline results from FAST-3 Firazyr Phase III trials for acute attacks of hereditary angioedema

Micell initiates enrollment in DESSOLVE I clinical trial of MiStent DES

CIHI study finds impact of H1N1 pandemic on Canadian hospitals

Sun Pharma receives FDA approval for generic Tiazac ANDA

Researchers report results from Phase III DEFINE study for coronary heart disease

TRITON–TIMI 38 substudy shows prasugrel reduces overall mortality rate in ACS patients

PLC Systems third quarter net loss decrease to $5,000

Pharmaxis to present ARIDOL Bronchial Challenge Test Kit at 2010 ACAAI

New Canadian Cardiovascular Society guidelines support clinicians in practicing evidence-based medicine

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News